Decision: Favourable

Study Title:

EPIK-B5: A phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed o

  • NREC Code:

    21-NREC-CT-172

  • Decision:

    Favourable

  • Meeting Date:

    12/01/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Janice Walshe

  • PI Institution:

    Cork University Hospital

  • Sponsor:

    Novartis Pharma AG

Scroll to Top
Skip to content